转移至皮肤的癌症很少见，尤其是转移至皮肤的宫颈鳞状细胞癌。本文对宫颈鳞癌皮肤转移患者的临床分析进行报道，以期让临床医生对该恶性肿瘤有一个大致的了解。对宫颈鳞癌皮肤转移患者进行回顾性分析，重点关注其临床表现、组织病理学、诊断、治疗及预后。6例宫颈鳞癌皮肤转移患者平均发病年龄为55.17±17.08岁，其中4例为单发灶，2例为多发灶。治疗策略包括局部切除孤立病灶、化疗、放疗或根据皮肤受累程度进行靶向治疗，免疫疗法在我们的病例中被证明具有良好的效果。 6名患者中，3名患者已去世，诊断至死亡时间约为5-6个月，3名患者还活着，生存时间为30至72个月。宫颈鳞癌皮肤转移罕见，且预后较差。通常伴随着其他内脏部位的复发性转移，因此需要早期准确的诊断。对于孤立的转移性病灶，早期发现并进行广泛切除手术和辅助放疗可以产生良好的结果。然而，在多发皮肤转移或同时转移至多个器官的情况下，治疗具有挑战性且预后不良。然而，随着医学的进步，联合化疗、免疫治疗和靶向治疗可以有效延长生存期，为宫颈癌皮肤转移患者带来新的希望。

Cancers that metastasize to the skin are rare, especially cervical squamous cell carcinoma to the skin. Here, we have reported clinical analysis of patients with cervical squamous cell carcinoma metastasize to skin, to obtain a general understanding of this malignancy for clinicians.A retrospective analysis of patients with skin metastasis from cervical squamous cell carcinoma was conducted, focusing on clinical manifestations, histopathology, diagnosis, treatment, and prognosis.The average age of onset for the six patients with skin metastasis from cervical squamous cell carcinoma was 55.17±17.08 years, with four cases presenting as solitary lesions and two cases as multiple lesions. Treatment strategies included local excision for isolated lesions, chemotherapy, radiotherapy, or targeted therapy based on the extent of skin involvement, and immunotherapy was proved to have promising results in our cases. Among the six patients, three have passed away with a diagnosis-to-death time of approximately 5-6 months, while three patients are alive, with survival times ranging from 30 to 72 months.Skin metastasis from cervical squamous cell carcinoma is rare and often accompanies recurrent metastases to other visceral sites, necessitating early and accurate diagnosis. For isolated metastatic lesions, early detection followed by wide excision surgery and adjuvant radiotherapy can yield favorable outcomes. However, in cases of multiple skin metastases or concurrent metastases to multiple organs, treatment is challenging with a poor prognosis. Nevertheless, with advancements in medicine, combination chemotherapy, immunotherapy, and targeted therapy can effectively prolong survival, offering new hope for patients with skin metastasis from cervical cancer.